IPXL - Impax Laboratories, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.85
+0.15 (+0.76%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.70
Open19.60
Bid0.00 x 0
Ask20.95 x 400
Day's Range19.50 - 20.05
52 Week Range12.80 - 25.70
Volume609,304
Avg. Volume896,303
Market Cap1.425B
Beta1.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of IPXL presentation 6-Mar-17 4:35pm GMT

    Impax Laboratories Inc at Raymond James Institutional Investors Conference

  • Why Is Impax Laboratories (IPXL) Down 1% Since Its Last Earnings Report?
    Zacks23 days ago

    Why Is Impax Laboratories (IPXL) Down 1% Since Its Last Earnings Report?

    Impax Laboratories (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Reuters27 days ago

    Impax reaches $20 mln deal to end trial over generic drug's delay

    Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn. According to the plaintiffs, Impax in 2008 settled a lawsuit it filed challenging a weak patent Medicis Pharmaceutical Corp held for Solodyn by agreeing to delay releasing its generic version until 2011. In exchange, Impax received $40 million, allowing Medicis to maintain its Solodyn monopoly longer, the plaintiffs allege.

  • Reuterslast month

    Impax settles retailers' antitrust cases over generic drug's delay

    Impax Laboratories Inc has reached a mid-trial settlement with retailers including CVS Health Corp and Rite Aid Corp who accused the drugmaker of entering into an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn. The deal, disclosed in papers filed in federal court in Boston on Sunday, resolved only part of the litigation now entering its third week of trial. Impax still faces claims by a class of consumers and insurers.

  • Teva’s Recent Launch of Generic Solodyn: What You Need to Know
    Market Realistlast month

    Teva’s Recent Launch of Generic Solodyn: What You Need to Know

    Solodyn has an indication for the treatment of inflammatory lesions of moderate to severe acne in patients 12 years and older. The generic version of Solodyn is the ninth generic tetracycline-class drug in Teva’s portfolio. According to IMS data, Solodyn Extended Release 65 mg and 115 mg tablets generated sales of ~$148 million in the United States in 2017.

  • How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017
    Market Realistlast month

    How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017

    Inside Merck's 2017 Performance: An In-Depth Look

  • Reuterslast month

    Impax broke U.S. antitrust law by delaying generic drug, jury told

    Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer. The trial in Boston federal court is one of a handful to have taken place since the U.S. Supreme Court in 2013 said so-called "pay-for-delay" settlements resolving pharmaceutical patent lawsuits can violate antitrust laws. A lawyer for Impax, in his opening statement, denied there was any such arrangement to delay Solodyn's entry to the market.

  • Reuterslast month

    Impax faces U.S. antitrust trial over generic acne drug's delay

    Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer. Jury selection began in Boston federal court in a case centered on an alleged "pay-for-delay" settlement, in which a generic manufacturer agrees to resolve legal challenges to a brand-name drug's patents and delay making a cheaper version. The trial is one of a handful to have taken place since the U.S. Supreme Court in 2013 said that such settlements, which also involve brand-name drug companies paying the generic manufacturers, can be found to be anticompetitive.

  • Reuters2 months ago

    Impax to pay $35 mln to settle part of Solodyn antitrust litigation

    Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn. The settlement was disclosed in papers filed in federal court in Boston on Saturday. It resolved part of the antitrust litigation Impax faces over Solodyn related to sales of the drug to direct purchasers such as retailers and wholesalers.

  • Depomed versus Peers in March 2018: Analyst Ratings
    Market Realist2 months ago

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.

  • Moody's2 months ago

    Amneal Pharmaceuticals, LLC -- Moody's rates Amneal's new term loan B1; outlook revised to positive

    Moody's Investors Service, ("Moody's") rated Amneal Pharmaceuticals, LLC's ("Amneal") proposed $2.7 billion senior secured term loan B1. Moody's also affirmed Amneal's current ratings ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of IPXL earnings conference call or presentation 1-Mar-18 1:30pm GMT

    Q4 2017 Impax Laboratories Inc Earnings Call

  • Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y
    Zacks2 months ago

    Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y

    Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.

  • MarketWatch2 months ago

    You still can’t buy this EpiPen competitor, eight months later

    Adamis’ Symjepi was billed as an EpiPen competitor, but the company’s search for a commercialization partner has prevented it from coming to market.

  • Have Investors Already Priced In Impax Laboratories Inc’s (NASDAQ:IPXL) Growth?
    Simply Wall St.2 months ago

    Have Investors Already Priced In Impax Laboratories Inc’s (NASDAQ:IPXL) Growth?

    Impax Laboratories Inc (NASDAQ:IPXL), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS over the last few months. AsRead More...

  • Associated Press2 months ago

    Impax Labs reports 4Q loss

    The Hayward, California-based company said it had a loss of $4.18 per share. Earnings, adjusted for one-time gains and costs, came to 11 cents per share. The results did not meet Wall Street expectations. ...

  • Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?
    Zacks2 months ago

    Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?

    Impax Laboratories (IPXL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • Loss-Making Impax Laboratories Inc (NASDAQ:IPXL) Expected To Breakeven
    Simply Wall St.2 months ago

    Loss-Making Impax Laboratories Inc (NASDAQ:IPXL) Expected To Breakeven

    Impax Laboratories Inc’s (NASDAQ:IPXL): Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. With the latest financial year loss of -US$472.03M and a trailing-twelve monthRead More...

  • Lee Ainslie Boosts 2 Health Care Positions
    GuruFocus.com2 months ago

    Lee Ainslie Boosts 2 Health Care Positions

    The guru added to his Envision Healthcare and Impax Laboratories holdings

  • Read This Before Buying Impax Asset Management Group plc (LON:IPX) For Its Upcoming £0.02 Dividend
    Simply Wall St.3 months ago

    Read This Before Buying Impax Asset Management Group plc (LON:IPX) For Its Upcoming £0.02 Dividend

    Have you been keeping an eye on Impax Asset Management Group plc’s (AIM:IPX) upcoming dividend of £0.02 per share payable on the 16 March 2018? Then you only have 3Read More...

  • Did Impax Asset Management Group plc’s (LON:IPX) Recent Earnings Growth Beat The Trend?
    Simply Wall St.3 months ago

    Did Impax Asset Management Group plc’s (LON:IPX) Recent Earnings Growth Beat The Trend?

    Assessing Impax Asset Management Group plc’s (AIM:IPX) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met orRead More...

  • Impax Laboratories Inc (NASDAQ:IPXL): Does -144.5% EPS Drop In A Year Reflect The Long-Term Trend?
    Simply Wall St.4 months ago

    Impax Laboratories Inc (NASDAQ:IPXL): Does -144.5% EPS Drop In A Year Reflect The Long-Term Trend?

    When Impax Laboratories Inc (NASDAQ:IPXL) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happeningRead More...

  • Capital Cube4 months ago

    ETFs with exposure to Impax Laboratories, Inc. : December 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Impax Laboratories, Inc. Here are 5 ETFs with the largest exposure to IPXL-US. Comparing the performance and risk of Impax Laboratories, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Impax Laboratories, Inc. : December 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Impax Laboratories, Inc. Here are 5 ETFs with the largest exposure to IPXL-US. Comparing the performance and risk of Impax Laboratories, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)